PDF(Pubmed)
Abstract：
UNASSIGNED: Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum-containing chemotherapy and immune checkpoint inhibitors. Common adverse events include rashes, peripheral neuropathy, and hyperglycemia. However, there are no reports on the development of myelodysplastic syndrome during enfortumab vedotin therapy in clinical settings.
UNASSIGNED: A 72-year-old male patient experienced prolonged and severe thrombocytopenia 18 weeks after the start of enfortumab vedotin therapy for metastatic urothelial carcinoma, requiring daily platelet transfusions. Bone marrow examination and chromosomal analysis confirmed the diagnosis of myelodysplastic syndrome. Treatment with eltrombopag proved to be effective.
UNASSIGNED: This is the first report of the development of myelodysplastic syndrome during enfortumab vedotin therapy in a clinical setting. Although rare, myelodysplastic syndrome can occur during enfortumab vedotin therapy.
UNASSIGNED: A 72-year-old male patient experienced prolonged and severe thrombocytopenia 18 weeks after the start of enfortumab vedotin therapy for metastatic urothelial carcinoma, requiring daily platelet transfusions. Bone marrow examination and chromosomal analysis confirmed the diagnosis of myelodysplastic syndrome. Treatment with eltrombopag proved to be effective.
UNASSIGNED: This is the first report of the development of myelodysplastic syndrome during enfortumab vedotin therapy in a clinical setting. Although rare, myelodysplastic syndrome can occur during enfortumab vedotin therapy.
摘要：
■Enfortumabvedotin是一种靶向Nectin-4的抗体-药物缀合物，用于治疗先前接受含铂化疗和免疫检查点抑制剂治疗的晚期尿路上皮癌。常见的不良事件包括皮疹，周围神经病变,和高血糖。然而,在临床环境中，没有关于enfortumabvedotin治疗期间骨髓增生异常综合征发展的报道。
一名72岁男性患者在开始enfortumabvedotin治疗转移性尿路上皮癌18周后出现长期和严重的血小板减少症，需要每天输注血小板。骨髓检查和染色体分析证实了骨髓增生异常综合征的诊断。用eltrombopag治疗被证明是有效的。
■这是关于在临床环境中enfortumabvedotin治疗期间骨髓增生异常综合征发展的第一份报告。虽然罕见，enfortumabvedotin治疗期间可发生骨髓增生异常综合征。
一名72岁男性患者在开始enfortumabvedotin治疗转移性尿路上皮癌18周后出现长期和严重的血小板减少症，需要每天输注血小板。骨髓检查和染色体分析证实了骨髓增生异常综合征的诊断。用eltrombopag治疗被证明是有效的。
■这是关于在临床环境中enfortumabvedotin治疗期间骨髓增生异常综合征发展的第一份报告。虽然罕见，enfortumabvedotin治疗期间可发生骨髓增生异常综合征。
